• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

How Effective are IUDs Compared to Tubal Ligation?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE: 

  • Schwarz et al. (Journal of General Internal Medicine, 2022) compare the effectiveness and safety of IUDs to laparoscopic tubal ligation for Medicaid clients

METHODS: 

  • Retrospective cohort study
    • California database
    • Medicaid claims data
  • Population
    • IUD placed or laparoscopic tubal ligation
    • Procedure performed between 2008 and 2014
  • Exposures
    • IUD placement
    • Tubal ligation
  • Study design
    • Study included stakeholder advisory board including patients and clinicians
    • Linear regression models used to test associations between contraceptive procedure and outcomes
    • Adjustments for sociodemographic variables and pre-procedure health status
  • Primary outcome
    • Contraceptive failure
    • Complications
    • Pain in first year post-procedure

RESULTS: 

  • Levonorgestrel IUD: 35,705 patients | Copper IUD: 23,628 patients | Tubal ligation: 23,965 patients
  • In unadjusted analyses, rates of pregnancy within 1 year were similar among the groups
    • Levonorgestrel IUD: 2.40%
    • Copper IUD: 2.99%
    • Tubal ligation: 2.64%
  • In adjusted analyses, compared to tubal ligation, pregnancy was less common following placement of
    • Levonorgestrel IUD
      • Adjusted incident rate ratio (aIRR) 0.72 (95% CI, 0.64 to 0.82)
    • Copper IUD
      • aIRR 0.92 (95% CI, 0.82 to 1.05)
  • Procedural complications such as infection were significantly less common with IUD placement than tubal ligation
    • IUD placement: 0.35%
    • Tubal ligation: 2.91%
  • Claims for pelvic and abdominal pain decreased in frequency over time regardless of contraceptive approach
  • At 6 to 12 months post-procedure, pelvic pain claims were less common after
    • Levonorgestrel IUD placement
      • aIRR 0.69 (95% CI, 0.65 to 0.73)
    • Copper IUD placement
      • aIRR 0.70 (95% CI, 0.66 to 0.75)
  • Results unchanged even after excluding patients at highest risk for post-procedure complications

CONCLUSION: 

  • Among patients with medicaid insurance, placement of a levonorgestrel or copper IUD is at least as effective at preventing pregnancy as tubal ligation 1-year post-procedure
  • Compared to tubal ligation, pregnancy within 1 year was
    • Lower than laparoscopic tubal ligation
    • Similar for copper IUD
  • Pain and infection were less common in patients who received an IUD vs tubal ligation
  • The authors state

As desire for reversal of tubal ligation is known to occur, it is important that all patients considering tubal ligation receive thorough counseling regarding the comparative safety and effectiveness of IUC prior to undergoing tubal ligation


Learn More – Primary Sources: 

Comparative Effectiveness and Safety of Intrauterine Contraception and Tubal Ligation

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

RAPID EC Trial Results: Levonorgestrel vs Copper IUD for Emergency Contraception
RCT Results: Levonorgestrel IUD vs Endometrial Ablation for Heavy Menstrual Bleeding
Can Copper and Levonorgestrel IUD Use Be Safely Extended?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site